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increased risk of several non-AIDS compli-
cations [2], including cardiovascular, renal, 
and bone disease.
Treating clinicians have to deal with this 
evolution in the challenges posed by HIV, 
and redefine aim and tools of HIV infection 
management. In particular, there is a growing 
necessity to attentively evaluate current and 
potential complications when prescribing the 
individual therapeutic regimen. Starting from 
this need, we developed two HIV-comorbid-
ity simulators that, basing on the evidence 
available in medical literature and starting 
from the current clinical and demographic 
features of the individual patient, project and 
IntroductIon
Infection with Human Immuno-deficiency 
Virus (HIV) may be considered one of the 
most challenging epidemics faced by health 
systems globally. In 2012, UNAIDS estimat-
ed a global prevalence of around 35.3 million 
people living with HIV (PLHIV). This num-
ber is increasing due to the availability of 
antiretroviral therapy (ART) and, mutually, 
mortality due to new infections is evidently 
declining across the globe [1].
Indeed, in the current era, most patients tak-
ing HAART achieve full and sustained viro-
logic suppression; however, HAART does 
not restore full health in PLHIV, who face 
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compare the risks of developing and worsen-
ing of nephropathy and osteopathy associated 
with possible antiretroviral (ARV) regimens. 
These simulators are embedded in a desktop, 
user-friendly software thought to be used by 
the treating physician during prescription 
discussion with his/her patients, in order to 
highlight expected clinical outcomes and 
healthcare resource consumption that may 
differ according to the strategy selected. The 
tool offers the possibility of customizing the 
projection by modifying the input data pro-
posed as default, selected across a deep re-
view of Italian and international literature 
and submitted for evaluation to a panel of 
infectious diseases experts.
In this supplement we present the sources 
and methods used in developing the tool, 
alongside a set of examples and the results of 
cohort-level validation runs.
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patients move to end-stage renal disease with 
the inevitable necessity of renal replacement 
by either dialysis or transplantation [18]. 
Providing the clinical practice with tools able 
to predict the occurrence or progression of 
CKD should aid the provision of necessary 
interventions that may stop or slow the pro-
gression to ESRD [19]. Echouffo-Tcheugui 
et al. systematically searched the literature 
in June 2012 for existing models predicting 
occurrence or progression of CKD in dif-
ferent populations [20]. eGFR cut off value 
(60 ml/min/1.73 m2) was uniformly used to 
define CKD. Age, sex, body mass index, dia-
betes status, systolic blood pressure, serum 
creatinine, a measure of proteinuria, and se-
rum albumin or total protein were the most 
frequently included predictors. Sadly, despite 
the need for it, any of CKD risk prediction 
tools weren’t found to be recommended in 
relevant clinical guidelines. And the impact 
of possible adoption of such tools in different 
clinical settings wasn’t assessed [20].
Among Echouffo-Tcheugui et al.’s 26 in-
cluded papers only one that aimed to pre-
dict 1-year probability of developing CKD 
among HIV-infected population [21]. This 
model only estimates new cases based on an 
ethnically limited sample, Japanese patients, 
and only among patients already receiving 
ARTs. Age, CD4 cell count, diabetes, pro-
teinuria, and eGFR at baseline were the vari-
ables found to be independently associated 
with the incidence of CKD.
Melting all HIV-specific and traditional risk 
factors in one predictive model of both inci-
dence and progression of CKD up to ESRD 
and death is our challenge.
renAl dIseAse evAluAtIon 
durIng bAselIne perIod
The evolution of renal disease during the 3 
years of baseline period is defined using a 
mathematical algorithm that merges evidence 
from published literature. The calculation, 
detailed in the next sub-section, takes into 
account:
 - The initial value of eGFR according to 
baseline patient characteristics (serum 
creatinine levels, age, sex and race);
bAckground – 
nephropAthy In plhIv
Before the introduction of ART, HIV-asso-
ciated kidney disease was the third leading 
cause of End Stage Renal Disease (ESRD) 
[3] and associated with higher mortality com-
pared to other causes of kidney disease [4]. 
The incidence of HIV-associated kidney dis-
ease markedly decreased after the introduc-
tion of ART and any increase in the incidence 
of kidney disease may be attributed to aging 
and traditional associated risk factors like 
diabetes and hypertension [5] and as a side 
effect of ARTs themselves [6-8]. ARTs are 
recommended for all symptomatic patients 
and those asymptomatic with CD4 cell count 
below 350/μL [9]. Due to highly comparable 
efficacy between Reverse Transcriptase In-
hibitors (RTI) or a ritonavir-boosted protease 
inhibitor based regimens, the initial choice 
should be personalized and be based on more 
than efficacy: co-morbidities, tolerance/safe-
ty and economic factors. On the side of RTIs, 
tenofovir and (emtricitabine or lamivudine) 
is one recommended option that proved to be 
more efficacious than other options from the 
same class like zidovudine/lamivudine [10] 
or stavudine/lamivudine [11].
However, one major safety concern with te-
nofovir is the possible negative impact on 
renal function [12]. Therefore, renal function 
assessment before and after initiation is criti-
cal; and in patients with renal dysfunction, 
tenofovir is better avoided [9]. This safety 
concern was observed to a lesser extent with 
other ARTs [6-8], yet more studied and con-
firmed with tenofovir [13-15]. In clinical 
practice, another problem arises regarding 
assessing the long term renal safety of teno-
fovir due to higher discontinuation rates with 
decreasing eGFR [7]. However, tenofovir 
wasn’t proved to be responsible for ESRD 
[16] and eGFR loss that may be attributed to 
tenofovir, in a long-term perspective, is rela-
tively mild [17].
Advanced stages of Chronic Kidney Disease 
(CKD) are devastating for patients and fami-
lies on one hand and, on the other hand, have 
major structural and economic impact on the 
health systems. This is particularly true when 
nephropathy model
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 - The reduction of eGFR due to clinical 
risk factors (diabetes, hypertension and 
macroalbuminuria incidence);
 - The acceleration/deceleration in eGFR 
reduction due to HIV risk factors (HIV 
infection, HIV severity, ART).
Initial renal function estimate
According to Guidelines [19], CKD sever-
ity is classified into five stage depending on 
the eGFR value; kidney function is normal 
in stage 1 and minimally reduced in stage 2 
(Table I).
The value of eGFR is calculated using differ-
ent predictive models available in literature. 
All available equations (for adult population) 
are incorporated in the software and imple-
mented in the models as starting points of 
the simulation of glomerular disease progres-
sion:
 - Cockcroft-Gault formula [22]
eGFR = (140 – Age) · W/72 · Sc · 
(0.85 if female)
where W is the real weight if BMI is normal 
(between 18.5 and 25) otherwise is calculat-
Stage eGFR1 Description treatment stage
1 90+ Normal KF but urine findings or structural 
abnormalities or genetic trait point to KD
Observation, control of BP. More on management of 
stages 1 and 2 CKD
2 60-89 Mildly reduced KF, and other findings (as 
for stage 1) point to KD
Observation, control of BP and risk factors. More on 
management of stages 1 and 2 CKD
32 30-59 Moderately reduced KF Observation, control of BP and risk factors. More on 
management of stage 3 CKD
4 15-29 Severely reduced KF Planning for end-stage renal failure. More on 
management of stages 4 and 5 CKD
5 <15 or on dialysis Very severe, or end-stage KF (sometimes 
call established renal failure)
Treatment choices. More on management of stages 
4 and 5 CKD
table I. CKD stages (elaborated from GLCKD 2002)
BP = Blood Pressure; KD = Kidney Disease; KF = Kidney Function
1 All eGFR values are normalized to an average surface area (size) of 1.73 m2
2 Stage 3 is usually divided in stage 3A (eGFR 45-59) and stage 3B (eGFR 30-44)
ed as the ideal BMI (18.5 if BMI < 18.5 and 
25 if BMI > 25) multiplied by the square of 
height. Resulting value is then standardised 
to BSA equal to 1.73 m2.
 - Modified Diet Renal Disease (MDRD) 
equation [23]
eGFR = k · Sc – 1.154 · Age – 0.203 · 
(0.742 if female) · (1.212 if black)
Where k is equal to 175 for standardized se-
rum creatinine and 186 otherwise.
 - CKD-EPI equation [24]
eGFR = 141 · min(Sc/k,1) – a · max(Sc/k,1) 
– 1.209 · 0.993 Age · (1.018 if female) · 
(1.159 if black)
Where k is 0.7 for females and 0.9 for males, 
a is 0.329 for females and 0.411 for males.
 - Mayo Quadratic (MQ) formula [25]
eGFR = exp(1.911 + 5.249/Sc – 2.114/Sc2 – 
0.00686 · Age – (0.205 if female))
The formula better estimates GFR in patients 
with preserved kidney function but it was not 
developed in a general population sample 
(elderly and African-American persons were 
underrepresented).
In all models, Sc is the serum creatinine val-
ue expressed in mg/dl, the age is measured in 
years and weight in kg.
eGFR decrease (without 
HIV influence)
Annual eGFR decreases are based on a recent 
microsimulation model developed by Hoerg-
er et al. [26]. The values are function of the 
initial value of eGFR, presence of diabetes 
and/or hypertension and evidence of persis-
tent macroalbuminuria (defined as albumin-
creatinine ratio ≥ 300 mg/g). Absolute annual 
reductions used in the model, expressed in 
ml/min/1.73 m2, are detailed in Table II.
Status Annual eGFR decrease
Htn Dm mA eGFR < 60 eGFR ≥ 60
No No No 0.65 0.65
Yes 4.2 0.72
Yes No 2.8 1.1
Yes 5.2 4.1
Yes No No 1.4 0.72
Yes 3.9 0.78
Yes No 2.8 1.1
No 5.2 4.1
table II. eGFR decrease according to clinical status (diabetes, hypertension and 
macroalbuminuria)
DM = Diabetes Mellitus; HTN = hypertension; MA = macroalbuminuria
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HIV factor risks
Five HIV-specific CKD risk factors were 
identified in the literature and incorporated in 
the model basing on the results of compara-
tive studies:
 - PLHIV versus HIV-uninfected people 
[14];
 - Late-stage HIV infection versus non-
AIDS PLHIV [14];
 - ART versus treatment-naïve PLHIV [14];
 - Nucleoside reverse transcriptase inhibi-
tors (NRTIs) pair:
 - specific for each drugs [6];
 - including vs not including tenofovir 
[13].
 - Third drug prescription [6].
Unfortunately the definition of renal disease 
is different in the studies: in Islam 2012 [14] 
and in Scherzer 2012 [13] renal disease is 
defined as eGFR < 60 ml/min/1.73 m² for 
greater than or equal to 3 months irrespec-
tive of kidney damage while in Tordato 2011 
[6] it is defined as a confirmed > 20% eGFR 
reduction from baseline (Table III).
eGFR progression algorithm 
during the baseline period
The progression of renal disease in the first 3 
years is evaluated according with the follow-
ing algorithm:
1. The initial eGFR value is calculated ac-
cording to patient characteristics;
2. Annual absolute eGFR reduction is deter-
mined according to clinical risk factors;
3. The absolute reduction is converted into 
an annual reduction rate (λBASAL) suppos-
ing exponential decay in eGFR value;
4. Using this rate, the time (TCRIT) at which 
eGFR falls below 60 ml/min/1.73 m2 is 
calculated;
5. TCRIT is corrected for HIV relative factors 
(excluding specific drugs influence);
6. A new annual reduction rate (λCRIT) is cal-
culated according to this corrected TCRIT;
7. λCRIT is corrected for specific third drug/
drug class as reported in section “HIV 
factor risk”;
CKD comparison Outcome measures 95% CI p-value
PLHIV vs. non-HIV (adjusted for sex, age and race) RR: 3.87 2.18-6.85
Late stage HIV vs. non-AIDS PLHIV RR: 3.32 1.86-5.93
ART vs. treatment-naïve RR: 0.54 0.29-0.99
NRTI pair [6]
 • Zidovudine/lamivudine RR: 1
 • Tenofovir/emtricitabine RR: 4.78 2.19-10.43 < 0.001
 • Tenofovir/lamivudine RR: 4.2 1.95-9.02 < 0.001
 • Abacavir/lamivudine RR: 1.88 0.63-5.65 NS1
 • Stavudine/lamivudine RR: 2.06 0.26-16.34 NS1
 • Didanosine/emtricitabine RR: 11.88 2.27-62.18 < 0.01
 • Didanosine/lamivudine RR: 1.81 0.38-8.59 NS1
 • Didanosine/stavudine RR: 2.54 0.31-20.46 NS1
 • Other (single agent or > 2 NRTIs) RR: 0.43 0.07-2.55 NS1
TNF vs. no TNF including regimes [13]
 • TNF exposure < 0.5 years HR: 1.30 0.91-1.86 NS2
 • TNF exposure 0.5-1 years HR: 1.85 1.35-2.53 < 0.001
 • TNF exposure 1-3 years HR: 1.69 1.26-2.27 < 0.001
 • TNF exposure > 3 years HR: 1.56 0.73-3.36 NS2
Third drug/drug class
 • NNRTI3 RR: 1
 • Non-indinavir single PI RR: 3.18 1.62-6.23 < 0.001
 • Non-indinavir PI/r RR: 2.15 1.25-3.70 < 0.01
 • NRTIs only RR: 9.39 1.79-49.32 < 0.01
table III – Relative risks related to HIV risk factors
HR = Hazard Ratio; PI = Protease Inhibitor; /r = ritonavir-boosted; RR = Relative Risk; TNF = tenofovir
1 Non significant RR was considered equal 1
2 Association of tenofovir exposure with CKD risk for less than one year was not taken into account since the model allows only switch of therapy at the 
end of the year of simulation. After 3 years the effect of tenofovir was not considered differential
3 Non NRTI
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The effect of the NRTI pair can be simulated 
according to two different data sets, Tordato 
2011 [6] and Scherzer 2012 [13].
 - Model 1 (based on Tordato 2011 [6]): 
According to the decay-rate related defi-
nition of renal disease in Tordato 2011 
(confirmed > 20% eGFR reduction from 
baseline), NRTI pair-specific RRs are ap-
plied directly to λCRIT . The new rate is 
used to estimate eGFR progression (un-
der the exponential hypothesis and ap-
plying half-cycle correction) only for the 
first two years of simulation, as for the 
third year of the baseline period we sup-
pose no influence of specific ART regi-
men.
 - Model 2 (based on Scherzer 2012 [13]): 
The influence of NRTI pair is modelled 
using HR reported in Scherzer 2012 (te-
nofovir vs no tenofovir) for all 3 years of 
the baseline period. The reported HR for 
eGFR < 60 ml/min/1.73 m2 is directly ap-
plied to λCRIT (similarly to model 1).
InterventIon on 
rIsk fActors
The model takes into account possible inter-
ventions on risk factors during the baseline 
period. Such HIV therapy related interven-
tions can be applied at most within 3 years 
from the start of simulation. Furthermore it is 
also possible to consider the reversibility of 
eGFR trend due to tenofovir discontinuation 
(if tenofovir was included in the current treat-
ment for at least 1 year), as reported in Jose 
2014 [15] (Table IV).
Start eGFR (ml/min/1.73 m2)
Overall
<60 60-90 >90
Tenofovir discontinuation
 • < 3 months 23.8 (8.5-39.0) 15.8 (10.0-21.6) 9.5 (4.7-14.3) 12.5 (8.9-16.1)
 • > 3 months -0.4 (-6.4-5.7) 0.3 (-0.8-1.4) 1.2 (0.12-2.1) 0.8 (0.1-1.5)
Weighted slopes1 6.550 4.550 2.975
table IV. eGFR slopes after tenofovir exposure
1 eGFR slopes after tenofovir discontinuation (< 3 months) according to start eGFR value were mediated by the overall eGFR slope (> 3 months) since 
detailed slopes lacked statistical significance
rIsk of esrd And mortAlIty
The association eGFR decline with subse-
quent progression to ESRD and mortality is 
investigated in a recent paper by Coresh et al. 
[27]. An individual meta-analysis was con-
ducted on 1.7 million participants with 12,344 
ESRD events and 223,944 deaths from 35 co-
horts in the CKD Prognosis Consortium.
ESRD is defined as initiation of renal replace-
ment therapy or death due to kidney disease 
other than acute kidney injury; all-cause mor-
tality are considered as well as cardiovascular 
(myocardial infarction, heart failure, stroke 
and sudden cardiac death) and non-cardio-
vascular mortality are also reported.
Results of the meta-analysis are presented in 
terms of absolute risk of ESRD or mortality 
at 1, 3, 5, and 10 years after the baseline pe-
riod as a function of the first value and the 
change of eGFR during a 2-year baseline pe-
riod [27]. Such values are used in this model 
to estimate ESRD risk and mortality accord-
ing to simulated progression of renal disease 
in a 3-years baseline period.
exAmple
Consider a white, male, 50 years old patient 
with a basal serum creatinine value of 0.8 
mg/dl, with hypertension, no diabetes and no 
macroalbuminuria; he is in treatment for HIV 
infection (no AIDS) with tenofovir/emtric-
itabine as backbone and a PI as the third drug.
Using CKD-EPI equation, initial eGFR results 
in 104 ml/min/1,73 m2 with an absolute annu-
al reduction of 0.72 that corresponds to 0.007 
annual reduction rate (λBASAL). The eGFR falls 
below 60 ml/min/1,73 m2 after 80 years (TCRIT) 
reducing to 38 years after applying HIV spe-
cific relative risks. By requiring that the eGFR 
reaches the threshold of 60 ml/min/1,73 m2 at 
TCRIT we get λCRIT equal to 0.014.
The progression of eGFR during the base-
line with these settings (current situation), 
according to different models, is shown in 
Figure 1 (continuous lines). If after the first 
year, patient switch from the current therapy 
to abacavir/lamivudine + NNRTI, the de-
creasing in eGFR reduces (Figure 1 – dotted 
lines). As reference value, the evolution of 
the same patient without HIV was considered 
applying only the annual decrease expected 
due to clinical risk factors.
In the current situation, the mean eGFR dur-
ing the first year of baseline period is 94 ml/
min/1.73 m2 with a reduction in 3 years of 
36.0% and 17.6%, according to predictions by 
model 1 model 2, respectively. After 10 years, 
the risk of ESRD results in 1.5% (IQR: 0.33-
4.3%) and mortality in 14% (IQR: 8.5-28%) 
for both models. The intervention on HIV 
Figure 1. CKD progression according to simulation algorithm (during 
baseline period); the evolution according to the two models is compared 
with the effect of intervention on risk factor
risk factors leads to a slowdown in the decay 
of eGFR: reduction in the first three years is 
in fact equal to 18.6% for model 1 and 7.3% 
for model 2 (Figure 2 and Figure 3). The new 
trend in eGFR results in a reduction of over 
60% in the risk of ESRD and 7% in mortality. 
Results for 1, 3, 5 and 10 years after the end of 
baseline period are reported in Table V.
Current situation (%)
[mean (IQR)]
Alternative situation (%)
[mean (IQR)]
Risk reduction (%)
[relative difference]
Risk of ESRD post baseline
 • after 1 year 0.023 (0.0051-0.068) 0.009 (0.002-0.026) 60.9
 • after 3 years 0.13 (0.029-0.38) 0.05 (0.011-0.15) 61.5
 • after 5 years 0.42 (0.093-1.2) 0.16 (0.036-0.48) 61.9
 • after 10 years 1.5 (0.33-4.3) 0.58 (0.13-1.7) 61.3
Mortality post baseline
 • after 1 year 0.77 (0.45-1.5) 0.66 (0.38-1.3) 14.3
 • after 3 years 2.7 (1.6-5.3) 2.3 (1.4-4.6) 14.8
 • after 5 years 5.2 (3.1-10) 4.5 (2.6-8.8) 13.5
 • after 10 years 14 (8.5-28) 13 (7.3-24) 7.1
table V. ESRD risk and mortality for the patient described in the example and effect of intervention on HIV risk factors
Figure 2. Bubble-plot shows, in order, relative reduction of eGFR in baseline 
period, 10 years ESRD risk and mortality according to model 1 (bubble size 
of eGFR reduction represents mean eGFR during first year of simulation 
while the sizes of ESRD risk and mortality bubbles are proportional to the 
probability not to exceed the predicted mean values)
Figure 3. Bubble-plot shows, in order, relative reduction of eGFR in baseline 
period, 10 years ESRD risk and mortality according to model 2 (bubble size 
of eGFR reduction represents mean eGFR during first year of simulation 
while the sizes of ESRD risk and mortality bubbles are proportional to the 
probability to not exceed the predicted mean values)
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of eGFR: reduction in the first three years is 
in fact equal to 18.6% for model 1 and 7.3% 
for model 2 (Figure 2 and Figure 3). The new 
trend in eGFR results in a reduction of over 
60% in the risk of ESRD and 7% in mortality. 
Results for 1, 3, 5 and 10 years after the end of 
baseline period are reported in Table V.
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Figure 3. Bubble-plot shows, in order, relative reduction of eGFR in baseline 
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probability to not exceed the predicted mean values)
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model vAlIdAtIon
In order to evaluate the predictive perfor-
mance of the model, a series of validations 
are performed using studies selected in the 
analysis but not used in the final formulation 
of the models. These external validations 
compare data observed in the studies with 
model predictions obtained simulating the 
experience of a cohort with the same distri-
bution of risk factors of the patients enrolled 
in the study; unfortunately, the overlapping 
among risk factors is not reported in detail in 
any of such studies, but it had to be inferred 
from epidemiological data. Furthermore, no 
study was identified that reported all evalu-
ated outcomes on the same population, so we 
tested the components of the overall model 
separately: predicted evolution of EGFR 
values has been compared (Figure 4) to data 
reported by Maggi in 2012 [29], while the ef-
fect of EGFR declining in a baseline period 
on risk of ESRD and mortality (Figure 5) 
was compared with data observed in [30-33], 
which were clinical studies conducted on a 
non-HIV population. Overall, the models’ 
predictions compare reasonably well with 
observed data: if EGFR decrease appears to 
be slightly overestimated, in particular by 
model 2 (ICONA-cohort based risks), this is 
offset by an opposite modest underestimation 
of subsequent hard end-points incidence.
Figure 4. Annual variation in eGFR: comparison between Maggi 2011 and 
simulation results
Figure 5. Comparison between simulation results and annual mortality (all-cause mortality) in Landray 2010 [30] (panel A), ESRD risk 
in Landray 2010 [30] (panel B), ESRD risk and mortality in Desai 2011 [31] (panel C) and in Tangri 2011 [32] (panel D), and risk factor 
associated with ESRD in Hallan 2009 [33] (panel E – Log scale)
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Osteopathy model
The present model has been planned to eval-
uate fracture risk in HIV-infected patients, 
based on the probability rate estimated by 
DeFRA adjusted for the HIV condition and 
for the administration of antiretroviral drugs 
with a well-known musculoskeletal toxicity. 
Furthermore, the desired model had to be 
able to predict the temporal evolution of the 
risk, taking into account the impact of pos-
sible interventions on modifiable CRFs.
frActure rIsk evAluAtIon
HIV-free fracture risk
The 10-year risk (10 YR) of multiple major 
fractures is calculated using DeFRA algo-
rithm:
logit (10YR) = a1Age + a2Age
2 + 
a3Age
3 + a4BMI + a5BMI
2 + a6T + a7T
2 + 
(a8Age + a9BMI) T + const
where age is expressed in years, BMI is the 
body mass index and T is the T-score. Coef-
ficients of equation are reported in Table VI.
Hip fracture incidence accounts for 13-33% 
of all non-vertebral fractures in the placebo 
arm of the largest RCTs focus on osteopo-
rotic treatment [40-44]. According to a recent 
cost-effectiveness analysis performed by Ad-
ami et al. [45] we assume a proportion of hip 
Coefficients multiple clinical fractures
a1
-0.54072
a2
0.00875
a3
-0.00004
a4
0.08077
a5
-0.00145
a6
-0.00654
a7
0.08938
a8
-0.00148
a9
-0.00102
const 5.98739
table VI. Coefficients of DeFRA algorithm equations
bAckground – frActure 
rIsk In plhIv
Bone strength is the result of bone mineral 
density (BMD) and bone microarchitecture. 
A decrease in BMD leads to deterioration of 
microarchitecture, leading to critical damage 
and porosity that weaken bone and increase 
the probability of fractures [34].
A case-finding approach for a pharmacologi-
cal treatment appears to be obligatory, at least 
with the available drugs. In Italy this problem 
has been approached by the health authori-
ties by granting drug reimbursement only for 
patients with a higher risk of fracture [35].
In the last years, it has become commonly 
accepted the notion that the risk of fracture 
does not depend exclusively by the BMD, but 
that many other clinical risk factors (CRFs) 
contribute to influence it. For this reason, 
Italian NHS identifies the patient to be tak-
en “in charge” based on various CRFs, like 
fractures history, steroid chronic treatment, 
smoking, in addition to BMD.
Many instruments have been developed 
to predict fracture risk, especially in post-
menopausal women; among these, FRAX®, 
with the WHO support, is the most used, 
estimating 10-years hip or other major os-
teoporotic fractures (clinical spine, forearm, 
hip or shoulder fracture) probability. The 
algorithm has been developed from study-
ing population-based cohorts from Europe, 
North America, Asia and Australia.
In Italy, as done in other countries, a national 
version of this model, called DeFRA, has 
been implemented in order to use it for regu-
latory scopes.
Despite HIV infection is one of the most re-
cently identified factor that leads to accelerat-
ed bone loss, with up to 25% of HIV-infected 
patients fulfilling osteoporosis criteria and up 
to 50% those for osteopenia [36-38], both the 
national and the original versions of the algo-
rithm do not include it among CRF.
The high morbidity, mortality and manage-
ment cost associated to bone fractures [39] 
make optimal monitoring and appropriate 
treatment essential, especially for patients at 
high risk, such as the HIV-infected popula-
tion.
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fracture of 20% corresponding to moderate to 
severe risk patients.
Once applied relative risks associated with 
CFRs, annual fracture rates are obtained 
from 10-year risks supposing an exponential 
growth trend of the risk.
Clinical risk factors
After the age of 40, the history of a previ-
ous fracture is one of the strongest CRF for 
new incident fractures [46-53]. The mean 
RR is 2.2, but the value depends on age and 
on the site and number of previous fractures 
[47,52,54].
A parenteral history of hip fracture is asso-
ciated with a significant risk both of all os-
teoporotic fractures and of hip fracture; the 
risk results independent of BMD [55]. Also a 
family history of any fracture in parents was 
associated with a modest but significantly in-
creased risk of any osteoporotic fracture and 
of hip fracture [55].
Smoking is a risk factor in particular for hip 
fractures, in part due to its negative effects on 
BMD and BMI. Smoking increases fracture 
risk even independently of age, BMD and 
BMI [56]. The relative risk depends consid-
erably on the number of cigarettes per day 
and it decreases with time since smoking ces-
sation [57].
Alcoholism is widely considered as a CRF 
for osteoporotic fractures and low bone den-
sity, with effects varying in a non-linear way 
according to intake [58]. Generally no sig-
nificant increase in risk is observed at daily 
intakes of less than 3 units while above this 
threshold, alcohol intake is associated with 
an increased risk factor both of hip and mul-
tiple fractures [59,60].
One of the most serious complications of cor-
ticosteroids is osteoporosis and an increased 
fracture risk. The increased risk is more 
strongly related to daily dose than to the cumu-
lative dose with a monotonic relationship [48].
Several early studies documented an in-
creased fracture risk in subjects with rheu-
matoid [61-63] and psoriatic arthritis [64], 
ankylosing spondyloarthritis [65-66] and in 
general with any connective tissue disease.
Relative risks associated with each CRF de-
scribed above and used in the model are re-
ported in Table VII.
HIV risk factors
The association between HIV infection and 
increased risk of fragility fracture was ex-
plored by Womack et al. by Cox regression 
models in male Veterans enrolled in the Vet-
erans Aging Cohort Study Virtual [67]. After 
adjusting for demographics, comorbid dis-
ease, smoking, alcohol abuse and BMI, HIV
infection results associated with a trend to-
wards an increased fracture risk (HR: 1.10; 
95% CI: 0.97-1.25).
Specific analyses carried out on female sam-
ples [68-69] revealed no excess risk in pa-
tients infected, so in the model no risk factor 
for women was introduced.
While HIV infection itself has adverse skel-
etal effects, the introduction of HAART may 
also contribute to accelerated bone loss [70]. 
Previous studies have suggested that ARVs 
drugs differ in their impact on bone health: 
tenofovir (TDF) has been found to be asso-
ciated with a greater decline in BMD than 
stavudine [71] or abacavir [72]. Also, earlier 
studies had suggested that exposure to pro-
tease inhibitors (PIs) decreased BMD [73], 
Clinical risk factor
DeFRA risk gradients
Hip fracture
multiple clinical 
fractures
Family history of hip fracture 1.6 1.2
Corticosteroid use1
 • > 5 mg prednisone equivalents 2.5 2.5
 • 2.5-5 mg prednisone equivalents 1.8 1.6
Previous vertebral o hip fracture2
 • One 2.2 2.2
 • More than one 4.0 4.0
Previous non-traumatic non-hip 
non-vertebral fracture2
1.4 1.4
Alcohol (> 3 units /day)3 1.5 1.2
Smoking4
 • <10 cigarettes /day 1.2 1.0
 • >10 cigarettes /day 1.9 1.5
Rheumatoid and psoriatic arthritis, 
ankylosing spondyloarthritis, any 
connective tissue disease
1.3 1.2
table VII. Gradients associated with each clinical risk factor (CRF) for the DeFRA 
project
1 Applicable to patients on corticosteroid therapy for more than 3 months. Prior treatment 
courses are not considered.
2 A fragility fracture is a fracture sustained after falling from a height not exceeding the 
body height or occurring after minimal or no trauma. Morphometric (even asymptomatic) 
moderate or severe (Genant- method) vertebral fractures are also included.
3 Currently drinking 3 or more units of alcohol. A unit of alcohol is defined as a 285 ml glass 
of beer, a 120 ml glass of wine, a 60 ml measure of aperitif, or a 30 ml measure of spirit.
4 Current smoking only: previous smoking is not considered.
and it has been recently suggested that ata-
zanavir is associated with increased risk of 
osteoporosis, compared to efavirenz [72]. Fi-
nally, antiretroviral initiation has been shown 
to be associated with a rapid and significant 
increase in levels of serologic markers of in-
creased bone turnover (which might signify 
increased bone fragility) [74-76].
The work of Bedimo et al. [77] was indicated 
by the expert panel as the most complete and 
consistent source, since it evaluated the ef-
fect of cumulative exposure to both TDF and 
PI. Four different exposure categories were 
selected:
 - Exposure to neither TDF nor PI (referent 
category);
 - Exposure to TDF, but not PI;
 - Exposure to PI, but not TDF;
 - Concomitant exposure to TDF and PI.
Concomitant exposure to both TDF and PI 
associated with a greater osteoporotic frac-
ture risk (HR: 1.16; 95% CI: 1.04-1.30) than 
exposure to either TDF without PI (HR: 1.11; 
95% CI: 1.01-1.21) or PI without TDF (HR: 
1.10; 95% CI: 1.01-1.22).
All values applied to annual fracture rates in 
the model are summarized in Table VIII.
Complex fracture risk
By averaging the fracture incidence ratios 
observed in the most important pivotal tri-
als it is apparent that approximately 25% of 
major fractures are identified vertebral frac-
tures, which comprise 33% of all vertebral 
fractures [45]. Major clinical fractures are on 
average made up of 25% vertebral fractures, 
20% hip fractures and 55% other non-verte-
bral fractures.
Complex fracture risk (including non-clinical 
vertebral fracture) thus results in the sum of 
clinical fracture risk and twice clinical verte-
bral fracture risk.
exAmple
Baseline patient characteristics and clinical/
HIV risk factors are reported in Table IX.
The current situation is compared with two 
interventions:
1. A first intervention on lifestyle (no alco-
hol and no smoking);
2. A second intervention on ART therapy 
(tenofovir and PI/r discontinuation).
Resulting fracture risks are reported in Ta-
ble X.
model vAlIdAtIon
As for the nephropathy model, also for the 
prediction of fracture risk, a series of valida-
tions are performed using studies not used in 
HIV risk factor
Hazard Ratio (HR)
male Female
HIV infection 1.10 1.00
TDF 1.11 1.11
PI 1.10 1.10
TDF+PI 1.16 1.16
table VIII. Influence of HIV infection and HAART therapy on annual osteoporotic 
fracture risk
Baseline value  • Age: 40 years
 • BMI: 22.86
 • T-score: -1
Clinical risk factors  • No family history of hip fracture
 • Corticosteroid use >5 mg
 • None previous fracture
 • Alcohol (>3 units /day)
 • Smoking <10 cigarettes /day
HIV risk factors  • Tenofovir/emtricitabine
 • Atazanavir/r
table IX. Patient characteristics
Fracture risk (%)
Year 1 Year 3 Year 5 Year 10
Current scenario
 • Hip fracture 0.8 2.3 3.8 7.5
 • Major clinical fracture 2.4 7.0 11.3 21.4
First intervention
 • Hip fracture 0.3 0.8 1.3 2.6
 • Major clinical fracture 1.3 3.8 6.2 12.0
Second intervention
 • Hip fracture 0.2 0.7 1.1 2.3
 • Major clinical fracture 1.1 3.3 5.4 10.5
table X. Estimated fracture risk in current and modified scenarios
Figure 6. Comparison between simulation results and 10-years risk of 
fracture in Johansson 2004 [78]
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the final formulation of the model. These ex-
ternal validations compare data observed in 
the studies with model predictions obtained 
simulating the experience of a cohort with 
the same distribution of risk factors of the 
and it has been recently suggested that ata-
zanavir is associated with increased risk of 
osteoporosis, compared to efavirenz [72]. Fi-
nally, antiretroviral initiation has been shown 
to be associated with a rapid and significant 
increase in levels of serologic markers of in-
creased bone turnover (which might signify 
increased bone fragility) [74-76].
The work of Bedimo et al. [77] was indicated 
by the expert panel as the most complete and 
consistent source, since it evaluated the ef-
fect of cumulative exposure to both TDF and 
PI. Four different exposure categories were 
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 - Exposure to neither TDF nor PI (referent 
category);
 - Exposure to TDF, but not PI;
 - Exposure to PI, but not TDF;
 - Concomitant exposure to TDF and PI.
Concomitant exposure to both TDF and PI 
associated with a greater osteoporotic frac-
ture risk (HR: 1.16; 95% CI: 1.04-1.30) than 
exposure to either TDF without PI (HR: 1.11; 
95% CI: 1.01-1.21) or PI without TDF (HR: 
1.10; 95% CI: 1.01-1.22).
All values applied to annual fracture rates in 
the model are summarized in Table VIII.
Complex fracture risk
By averaging the fracture incidence ratios 
observed in the most important pivotal tri-
als it is apparent that approximately 25% of 
major fractures are identified vertebral frac-
tures, which comprise 33% of all vertebral 
fractures [45]. Major clinical fractures are on 
average made up of 25% vertebral fractures, 
20% hip fractures and 55% other non-verte-
bral fractures.
Complex fracture risk (including non-clinical 
vertebral fracture) thus results in the sum of 
clinical fracture risk and twice clinical verte-
bral fracture risk.
exAmple
Baseline patient characteristics and clinical/
HIV risk factors are reported in Table IX.
The current situation is compared with two 
interventions:
1. A first intervention on lifestyle (no alco-
hol and no smoking);
2. A second intervention on ART therapy 
(tenofovir and PI/r discontinuation).
Resulting fracture risks are reported in Ta-
ble X.
model vAlIdAtIon
As for the nephropathy model, also for the 
prediction of fracture risk, a series of valida-
tions are performed using studies not used in 
HIV risk factor
Hazard Ratio (HR)
male Female
HIV infection 1.10 1.00
TDF 1.11 1.11
PI 1.10 1.10
TDF+PI 1.16 1.16
table VIII. Influence of HIV infection and HAART therapy on annual osteoporotic 
fracture risk
Baseline value  • Age: 40 years
 • BMI: 22.86
 • T-score: -1
Clinical risk factors  • No family history of hip fracture
 • Corticosteroid use >5 mg
 • None previous fracture
 • Alcohol (>3 units /day)
 • Smoking <10 cigarettes /day
HIV risk factors  • Tenofovir/emtricitabine
 • Atazanavir/r
table IX. Patient characteristics
Fracture risk (%)
Year 1 Year 3 Year 5 Year 10
Current scenario
 • Hip fracture 0.8 2.3 3.8 7.5
 • Major clinical fracture 2.4 7.0 11.3 21.4
First intervention
 • Hip fracture 0.3 0.8 1.3 2.6
 • Major clinical fracture 1.3 3.8 6.2 12.0
Second intervention
 • Hip fracture 0.2 0.7 1.1 2.3
 • Major clinical fracture 1.1 3.3 5.4 10.5
table X. Estimated fracture risk in current and modified scenarios
Figure 6. Comparison between simulation results and 10-years risk of 
fracture in Johansson 2004 [78]
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compare reasonably well with the observed 
data, although some underestimation in the 
fracture risk is detected when comparing 
with Johansson 2004 [78] and the low risk 
subgroups in Kraege 2013 [79], while the op-
posite (slight overestimation) is observed for 
the high-risk subgroups in the latter study. In 
any case, all predictions fall within the re-
ported confidence intervals.
Figure 7. Comparison between simulation results and 5-years risk of fracture based on age and femoral T-score in women (panel A) 
and in men in Krege 2013 [79]
patients enrolled in the study; unfortunately, 
the overlapping among risk factors is not re-
ported in detail in any of such studies, but it 
had to be inferred from epidemiological data 
and clinical knowledge.
The Figure 6 and Figure 7 report and com-
pare the results of such simulated trials with 
the results reported in the papers. Again, 
the cohort- and subgroup-level predictions 
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HAART changed the natural history of HIV 
infection, transforming it in a chronic disease. 
In common with other chronic disease, the 
life-long exposure to therapeutic regimens is 
associated with an increased risk of second-
ary co-morbidities. We feel that the current 
perceptions of this risk increase, and the cor-
responding managing skills of treating physi-
cians, are far from being optimal, and there-
fore aimed at developing a practical tool that 
could aid them to assess these risks and the 
potential of interventions to modulate them.
Concentrating on renal function and fracture 
risk, we reviewed the available literature 
and propose two disease progression models 
build upon the most reliable sources, as as-
sessed by confrontation with infectivologists 
and expert clinicians in the respective fields. 
HIV-specific risk factors identified through 
this process (Infection itself, AIDS, and com-
ponents of HAART) were integrated with 
published risk prediction models to establish 
these proposed models.
Some cohort-level validation runs performed 
by simulating clinical trials providing both 
the needed input data and outcome indica-
tors show that the presented models are able 
to reproduce average results with acceptable 
Discussion and conclusions
accuracy. For a rigorous and formal testing 
of the predictive capability of the models, 
however, the predictions should be compared 
at the individual level on a large clinical da-
tabase: this type of analysis is planned in the 
near future.
Nevertheless, given the practical aim of the 
tools, we believe that their capability of cor-
rectly indicating the expected course of the 
disease, and to be sensitive to the interplay 
of concomitant risk factors, is reassuring in 
regard to their intended use: providing a ra-
tional, credible and easily usable aid for a 
more informed decision-making process in 
HAART prescribing.
Furthermore, the ability of the present mod-
els to reliably predict hard outcomes at the 
cohort level render them suitable to be in-
cluded in pharmacoeconomic simulation 
models developed for the comparative as-
sessment of the economical consequences of 
different prescribing strategies that expand 
their focus beyond pharmaceutical acquisi-
tion costs, taking into the right consideration 
other items of healthcare resource consump-
tion, in particular those needed for monitor-
ing and managing the comorbidities of HIV 
in the HAART era.
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